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Abstract
Introduction  and  Objectives:  Reperfusion  and  revascularization  therapies  play  an  important
role  in  the  management  of  coronary  heart  disease  and  have  contributed  to  decreases  in case
fatality rates.  We  aimed  to  describe  the  use  of  these  therapies  for  the  treatment  of  acute
coronary syndrome  (ACS)  patients  over  time  in Portugal.
Methods:  PubMed  was  searched  in  July  2012.  The  proportion  of  patients  treated  with  fibri-
nolysis,  primary  percutaneous  coronary  intervention  (PCI),  any  PCI  and  coronary  artery
bypass grafting  (CABG)  was  described  according  to  type  of  ACS:  STEMI  (≥90%  patients  with
ST-segment  elevation  or  Q-wave  myocardial  infarction),  NSTE-ACS  (≥90%  patients  with  non-ST-
segment  elevation  ACS)  and mixed  ACS  (all  others).
Results:  We  identified  41  eligible  studies,  published  between  1989  and  2011.  Twenty-eight
reported on samples  considered  representative  of  ACS  patients  treated  in Portugal.  The  small
number of  estimates  of  the  use  of  each  treatment  in  STEMI  and  NSTE-ACS  patients  precluded
identification  of  any  time  trend.  In  the  last  20  years,  the  proportion  of  mixed  ACS  patients
treated with  fibrinolysis  decreased  and  the  use  of  PCI  increased,  while  the  use  of  CABG  did  not
change.
Conclusions:  The  general  pattern  of  the  use of  reperfusion  and  revascularization  is in accor-
dance with  that  reported  in other  developed  countries,  reflecting  a  favorable  trend  in  the
quality of  care  of ACS  patients.  The  relatively  small  number  of  estimates  on  the  same  proce-
dure in comparable  patients  limits  the  generalizability  of  the  conclusions,  and highlights  the
need for  systematic  approaches  to monitor  the  use  of  treatments  over  time.
© 2013  Sociedade  Portuguesa  de Cardiologia.  Published  by  Elsevier  España,  S.L.U.  All  rights
reserved.
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Uso  de  procedimentos  de  reperfusão  e  revascularizac¸ão  na  síndrome  coronária  aguda
em  Portugal:  revisão  sistemática
Resumo
Introduc¸ão  e objetivos:  A reperfusão  e revascularizac¸ão  desempenham  um  importante  papel
no tratamento  da  doenc¸a coronária  contribuindo  para  a  diminuic¸ão  da  letalidade.  Foi  nosso
objetivo descrever  o uso  destes  procedimentos  no tratamento  da  síndrome  coronária  aguda
(SCA) ao longo  do tempo  em  Portugal.
Métodos:  A pesquisa  foi  efetuada  na  Pubmed  em  julho  de 2012.  A proporc¸ão  de doentes
tratados com  fibrinólise,  angioplastia  primária,  qualquer  tipo  de angioplastia  e  cirurgia  de
revascularizac¸ão coronária  (CABG)  foi descrita  de  acordo  com  o  tipo de SCA:  SCA supra-ST
(quando a  proporc¸ão  de doentes  com  elevac¸ão  do  segmento  ST  ou  enfarte  do miocárdio  com
ondas Q  era  ≥90%),  SCA  sem-ST  (quando  a  proporc¸ão  de doentes  com  SCA  sem  elevac¸ão do
segmento ST  era  ≥90%)  e  SCA  misto  (restantes  casos).
Resultados:  Foram  identificados  41  estudos  publicados  entre  1989  e 2011.  Vinte  e oito  estudos
descreveram  amostras  representativas  dos  doentes  com  SCA  tratados  em  Portugal.  O  baixo
número de  estimativas  de cada  tratamento  nos  doentes  com  SCA  supra-ST  e sem-ST,  impossibi-
litou a  observac¸ão de tendências  temporais.  Nos  últimos  20  anos,  a  proporc¸ão  de  doentes  com
SCA misto  tratados  com  fibrinólise  diminuiu,  o  uso  de  angioplastia  aumentou,  enquanto  o uso
de CABG  não  se  alterou.
Conclusões:  O  padrão  do  uso  destes  tratamentos  está  de  acordo  com  dados  publicados  noutros
países desenvolvidos,  refletindo  uma  tendência  favorável  na qualidade  dos  cuidados  prestados.
O baixo  número  de  estimativas  do mesmo  procedimento  limitou  a  generalizac¸ão  de conclusões,
reforc¸ando a  necessidade  de alternativas  para  monitorizar  o  uso  de tratamentos  ao  longo  do
tempo.
© 2013  Sociedade  Portuguesa  de  Cardiologia.  Publicado  por  Elsevier  España,  S.L.U.  Todos  os
direitos reservados.
Introduction
Coronary  heart  disease  (CHD)  is  responsible  for  7.3  mil-
lion  deaths  yearly  worldwide,  corresponding  to  12.8%  of  all
deaths.1 In  Portugal,  CHD  was  responsible  for  23%  of  cardio-
vascular  deaths  in 2009,2 though  mortality  rates  have  been
decreasing  since  the  1980s,  as  in  most  developed  countries.3
The  increasing  use  of  evidence-based  treatments  for
acute  coronary  syndrome  (ACS),  including  reperfusion  ther-
apy  and  revascularization  procedures,  has  been  reported  to
explain  up  to half  of  the  decrease  in CHD  mortality  rates
in  several  developed  countries.4,5 Continuous  and  comp-
rehensive  monitoring  of  the  use  of  reperfusion  and  revas-
cularization  therapies  for  ACS  patients  in routine  clinical
practice  is  thus essential  to  evaluate  the  quality  of  care.
The  Portuguese  Registry  of  Acute  Coronary  Syndromes
provides  data  on  a  large  number  of  ACS  events  in  the
last  decade,  but  only  patients  admitted  to  some  car-
diology  departments  in the country  are registered  and
consecutive  recruitment  is not ensured,  possibly  limiting
its  representativeness.6 Other  studies,  based  on samples  of
episodes,  mainly  single-center  and resulting  from  the  initia-
tive  of  local  physicians  or  academic  researchers,  have  been
published  and  could  complement  the registry  data  with  cov-
erage  of  other  institutions  and departments  and a  greater
time  span.
Therefore,  we  performed  a systematic  review  of  pub-
lished  studies  reporting  on  the use  of  reperfusion  and
revascularization  procedures  in patients  with  ACS  in  Portu-
gal.
Methods
Search  strategy
We  searched  PubMed  from  inception  until  July  2012  to  iden-
tify  original  reports  providing  data  on  the proportion  of
patients  with  ACS,  stable  angina  and  heart  failure  treated
with  pharmacological  and  non-pharmacological  therapies
in Portugal.  The  search  expression  is  provided  in the  sys-
tematic  review  flowchart  (Figure  1). This  report  focuses
on  reperfusion  and revascularization  procedures  in ACS.
The  reference  lists  of  review  articles  on  treatment  of  ACS
patients  were  screened  to  identify  other  potentially  eligible
original  studies.
Screening  of reference  lists
Two  reviewers  independently  assessed  the  studies  in two
steps,  following  the  same  predefined  criteria,  to  determine
the  eligibility  of  each report.  In the first  step  irrelevant  stud-
ies  were  excluded  on the  basis  of  the title  and  abstract
only;  when  the  abstract  of  a  particular  article  was  not
available,  the article  was  selected  for further  assessment,
except  when the  title  unequivocally  presented  evidence  for
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682 publications
(626 identified through PubMed search and 56 from bibliographics references of reviews)
humans[mesh] AND (portugal[ad] OR portugal OR “acta med port”[journal] OR “rev port cardiol”[journal] OR “rev port
cir cardiotorac vasc”[journal] OR lisboa[ad] OR lisbon[ad] OR (porto[ad] NOT (brasil[ad] OR brazil[ad] OR faro[ad] OR
gaia[ad]) AND (“ischemic heart disease” OR “coronary artery disease”[mesh] OR “coronary heart disease” OR “acute
coronary syndrome”[mesh] OR “myocardial infraction”[mash] OR “acute myocardial infraction” OR “angina
pectoris”[mesh] OR “angina, unstable”[mesh] OR “stable angina” OR “chronic angina” OR angor OR “heart
failure”[mesh]) AND (hospitalization[mesh] OR (therapeutics[mesh] OR treatments OR drug OR medication) OR
“myocardial revascularization”[mesh] OR (“coronary artery bypass graft” OR cabg) OR (angioplasty, balloon[mesh] OR
ptca OR “percutaneous transluminal coronary angioplasty” OR “primary angioplasty”) OR “hospital resuscitation” OR
(thrombolysis OR “fibrinolytic agents”[pharmacological action] OR actilyse OR streptase OR rapilysin OR metalyse) OR
aspirin[mesh] OR  (“adrenergic beta-antagonists”[pharmacological action] OR “beta blockers”) OR (“ace inhibitors” or
“angiotension-converting enzyme inhibitors”[pharmacological action]) OR “platelet iib/iiia inhibitors” OR
clopidogrel[substance name] OR heparin[mesh] OR “platelet aggregation inhibitors"[pharmacological action] OR statins
OR warfarin[mesh] OR spironolactone[mesh] OR rehabilitation OR “angiotensin ii type 1 receptor
blockers"[pharmacological action] OR (“resynchronization therapy” OR “cardiac resynchronization therapy” OR crt OR
''biventricular pacemaker”) OR (“implantable cardiodefibrillator” OR “implantable cardio defibrillator” OR “implantable
cardiac defibrillator”) OR “implantable cardioverter defibrillator” OR icd) OR (heart transplant* OR heart
transplantation[mesh terms] OR “allogeneic graft”) OR Cardiac Surgical Procedures[mesh]) AND (english[lang] OR
spanish[lang] OR portuguese[lang])
Reasons for exclusion from the study:
• not involving humans – 6
• case reports-58
• reviews, editorials or comments – 244
• not involving Portuguese hospitals – 46
• patients' selection dependent on having
undergone some diagnostic or treatment under
study – 75
• not providing data on treatments – 110
• insufficient information to characterize the
population – 10
• data described in other reports on the same
studies – 53
Reasons for exclusion from this analysis:
• data only on stable angina – 3
• data only on heart failure – 29
• no data on reperfusion or revascularization - 7
80 publications
41 publications with data on reperfusion and/or revascularization therapies *
(28 unselected  )
21 studies with data on
reperfusion therapy
(12 unselected)
28 studies with data on
revascularization therapy
(22 unselected)
20 studies with
data on fibrinolysis
(12 unselected)
Number of studies :
total (unselected)
STEMI – 6 (3)
Mixed ACS – 14 (9)
5 studies with
data on primary PCI
(4 unselected)
Number of studies :
total (unselected)
STEMI – 3 (2)
Mixed ACS – 2 (2)
24 studies with
data on PCI
(21 unselected)
Number of studies :
total (unselected)
STEMI – 3 (2)
NSTE-ACS – 9 (8)
Mixed ACS – 14 (13)
20 studies with
data on CABG
(15 unselected)
Number of studies :
total (unselected)
STEMI – 1 (1 )
NSTE-ACS – 10 (8)
Mixed ACS – 12 (8)
Figure  1  Flowchart  of the  systematic  review.  CABG:  coronary  artery  bypass  grafting;  PCI:  percutaneous  coronary  intervention;
STEMI: 90%  or more  patients  with  diagnosis  of  ST-segment  elevation  myocardial  infarction  or  Q-wave  myocardial  infarction;  NSTE-
ACS: 90%  or  more  patients  with  diagnosis  of  non-ST-segment  elevation  ACS;  mixed  ACS:  mixture  of  patients  with  several  types  of  ACS.
* If  a  study  provided  data  on  treatment  with  both  reperfusion  and  revascularization,  it  contributed  to  both  groups.  If  a  study
provided data  on more  than  one  diagnostic  category,  it  contributed  to  all  groups.
† The  sample  was  considered  selected  when  inclusion  of  patients  was  dependent  on  having  undergone  some  diagnosis  or  treatment
procedure; otherwise,  it  was  considered  unselected.
exclusion  (e.g.  case  report).  The  full  texts  of  studies
selected  for  the second  step  were  then  assessed  to decide
on  their  eligibility  and  availability  of  relevant  data.
The  decisions  made  independently  by  the  two  review-
ers  were  compared  in  the two  phases  and disagreements
were  resolved  by  consensus  or  after  discussion  with  a  third
researcher,  if necessary.
The  criteria  for  exclusion  of  studies  were  the follow-
ing:  not involving  humans  (e.g.  in-vitro  studies;  animal
research);  case  reports;  reviews,  editorials  or  comments;
not  involving  Portuguese  hospitals;  involving  ACS  patients
whose  selection  was  dependent  on  having  undergone  a  par-
ticular diagnosis  or  treatment  procedure  under  study  and
with  no  information  on  any  other  procedure  (e.g.  samples
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including  only  patients  who  underwent  PCI);  not providing
data  on  treatments  in ACS  patients;  providing  insufficient
information  to  characterize  the  population  (e.g.  not provid-
ing  information  on  patients’  age or  sex,  or  sample  size).
When  more  than  one  study  provided  data  on  patients
with  the  same  diagnosis,  selected  using  the same  criteria,
from  the  same  institution  and  in overlapping  periods,  we
included  the  one  that covered  the  longest  time  period;  if
the  same  time  period  was  considered,  the one  with  the
largest  sample  size  was  included,  or  in cases  of  similar  sam-
ple  size,  the  one  that  provided  information  on  more  eligible
treatments.  When  there  were  two  studies  that  included
ACS  patients  admitted  to  the same  hospital  with  part  of
the  data  collection  period  overlapping,  we  included  only
the  one  with  the larger  sample  size,  even  though  over
a  shorter  time  period,7 since  the other  included  a group
selected  from all  patients  with  ACS.8 When  two  publica-
tions  studied  the  same  sample,  but  reported  complementary
results  on  eligible  treatments,  both  articles  were  included
but  the  information  on  each eligible  treatment  for  each
specific  diagnosis  was  considered  only  once  in the  data
analyses.
Data  extraction
Papers  were  scrutinized  using a  standardized  data  extraction
sheet,  to collect  information  on:  first author,  publication
year,  year  or  period  of  data  collection,  geographical  cover-
age  and  department  where  patients  were  recruited,  sample
characteristics  (study  population,  diagnosis,  type  of  episode
[first  vs.  recurrent],  sex,  age and  sample  size),  proportion
of patients  who  received  treatments  (fibrinolysis,  primary
and  non-specified  PCI  and  coronary  artery  bypass  grafting
[CABG]).  If  only  the absolute  number  of  patients  treated
was  available,  the  proportion  was  calculated  by  dividing
by  the  stratum-specific  sample  size.  When  an  article  pre-
sented  data  stratified  by  a variable  with  no  relevance  to  our
analysis  (e.g.  diabetic  vs.  non-diabetic  patients),  we  cal-
culated  the  weighted  average  of the proportions  over  all
strata.
All types  of PCI  (including  primary  PCI)  were considered
in  the  analysis  of  this  procedure  as  revascularization  ther-
apy.  The  proportions  of patients  undergoing  percutaneous
and  surgical  revascularization  procedures  were  described
only  when  performed  during  the initial  hospitalization  for
the  acute  event.  We  considered  two  types  of  study  popu-
lation  in  terms  of  their  representativeness  of ACS  patients
treated  in  Portuguese  institutions:  when  patient  selection
was  dependent  on  having  undergone  a treatment  or  a
diagnostic  procedure  (e.g.  patients  referred  for viability
tests;  patients  undergoing  coronary  angiography),  the popu-
lation  was  considered  selected;  otherwise,  it was  considered
unselected.
When  possible,  year-,  sex-,  age-  and  diagnosis-specific
estimates  were  extracted.
Data  analysis
All  studies  are  described  in the Supplementary  Table  avail-
able  online;  only  those  relying  on  unselected  samples  of
patients  are  represented  in the  forest  plots. Although
sex- and age-specific  estimates  were  extracted  and  are
shown  in the detailed  Supplementary  Table,  these  were  sel-
dom  available  and  for descriptive  purposes  the results  for
the total  sample  are  always  presented  in  the forest  plots,
stratified  only by  diagnosis.
The  proportion  of patients  who  underwent  each  pro-
cedure  was  described  according  to  type  of  ACS.  However,
given  that  reports  did  not  systematically  stratify  according
to  this  criterion,  patient  samples  were  classified  into one
of the  following  three  categories,  according  to  the  propor-
tion  of  different  ACS  patients  included:  STEMI  (90%  or  more
patients  with  a  diagnosis  of  ST-segment  elevation  myocardial
infarction  (STEMI)  or  Q-wave  myocardial  infarction  [MI]),
NSTE-ACS  (90%  or  more  patients  with  a  diagnosis  of  non-
ST-segment  elevation  ACS  [NSTE-ACS]),  and  mixed  ACS (if
neither  of  these  criteria  was  satisfied).
Results
We  identified  41  eligible  studies  providing  data  on  ACS
patients  who  underwent  reperfusion  and/or  revasculariza-
tion  therapies,  21  presenting  data  on  reperfusion  and  28  on
revascularization  (Figure  1), published  between  1989  and
2011  (Supplementary  Table  1, available  online).
Over  three-quarters  of  the studies  reported  data  from
a  single  institution,  mainly  from  the  Lisbon  region.  Three
studies  were  based on  national  registries  that  covered  sev-
eral regions  of the country.6,9,10 The  vast  majority  of  studies
recruited  patients  in cardiology  departments.  Two-thirds  of
the  studies  included  unselected  populations.  More  than  half
of  the studies  included  both  first  and recurrent  episodes
and  four studies  reported  exclusively  on  first  episodes.11--14
The  sample  size  ranged  from 21  to  22  482  patients,  and
almost  40%  of  the studies  involved  samples  between  100
and  500  patients.  Seven  samples  included  mostly  STEMI
patients,  10  mostly  NSTE-ACS  patients  and 27  a  mixture
of patients  with  several  types  of  ACS.  Five studies  pre-
sented  sex-specific  estimates,10,14--17 and only  two  presented
age-specific  estimates18,19 (Supplementary  Table  1, avail-
able  online).
As  expected,  data  on  reperfusion  were available  only
for  STEMI and  mixed  ACS  patients  (Figure 1). Only  three
studies  provided  estimates  of  the  use  of  reperfusion  in
STEMI patients.  In  more  recent  years,  one  study  conducted
in  Faro reported  the use  of  fibrinolysis  in 16.5%  of  STEMI
patients  in 2008,20 while  a  report  from  the National  Reg-
istry  of  Acute  Coronary  Syndromes  showed  a mean  of 43.7%,
representing  many  cardiology  centers  across  the  country
over  several  years.6 The  same  two  studies  reported  the
use  of  primary  PCI  in 41.4%  and  19.2%  of STEMI  patients,
respectively.6,20 For  mixed  ACS  patients  there  was  a larger
number  of observations;  fibrinolysis  was  used in a  quarter  to
a  half  of  patients  in the late  1990s,  decreasing  to  less  than
10%  over  the next decade.  Two reports  published  10  years
apart,  in 2001  and  2011,  showed  an  increase  in the  use  of
primary  PCI  in mixed  ACS  patients,  from  less  than  10%  in a
sample  of  patients  from  several  cardiology  centers  across
the  country10 to  approximately  50%  in  a  single  cardiology
center  in Lisbon19 (Figure  2).
Percutaneous  revascularization,  including  both  emer-
gent and  elective  procedures  during  hospitalization  for  an
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First author, 
publication year
Geographical
coverage
Episode
type
Male, % Age*, yrs Sample
size
Proportion of patients treated, %
STEMI
Caires G, 2000 
Trigo J, 2008 
Santos JF, 2009
STEMI 
Trigo J, 2008 
Santos JF, 2009
MixedACS
Ribeiro H, 1995
Fernando PB, 1996
Carôla B, 1996
Silva P,1997
Caires G, 1998
Bettencourt P, 2000
Morais J, 2001
Timóteo AT, 2011
Piçarra BC, 2011
MixedACS
Morais J, 2001
Timóteo AT, 2011
V.F.Xira
Porto
Lisboa
Lisboa
Gaia
Carnaxide
Porto
Portugal
Lisboa
Évora
F+R
F+R
F+R
F+R
F 65 (13) 907
278
278
10.212
10.212
68 (14)
65 (14)
68 (14)
65 (14)
66
65.7
76.2
65.7
76.2
81
67
73
86.1
82.5
84.2
72.9
69.2
72.9
69.2
55.3
F
F+R
F+R
F+R
F+R
F+R
F+R
F+R
F+R
-
-
Funchal
Faro
Faro
Portugal
Portugal
Portugal
61.8 (11.4)
62.2 (13.7)
64 (12)
57.5 
21
191
1.319
504
178
101
1.366
1.242
1.366
1.242
132
0     10   20    30   40   50   60    70   80   90
0     10   20    30   40   50   60    70   80   90
56 (12)
58.3 (12.6)
65.1 (12.9)
65.1 (12.9)
64.2 
64.2 


83.2 (2.8)
Fibrinolysis
Primary PCI
Figure  2  Proportion  of  acute  coronary  syndrome  patients  treated  with  reperfusion  therapies  (fibrinolysis  and  primary  PCI)  in
Portugal, estimated  in unselected  samples  of  patients.  F:  first  episode;  mixed  ACS:  mixture  of  patients  with  several  types  of  ACS;
NSTE-ACS:  90%  or  more  patients  with  diagnosis  of  non-ST-segment  elevation  ACS;  PCI:  percutaneous  coronary  intervention;  R:
recurrent episode;  STEMI:  90%  or  more  patients  with  diagnosis  of  ST-segment  elevation  myocardial  infarction  or  Q-wave  myocardial
infarction. *  Age  is presented  as mean  (SD)  unless  otherwise  specified; † mean  age; ‡ median  age.
First author,
publication year
Age*, yrsEpisode
type
Male, % Sample
size
PCI, %Geaographical
coverage
STEMI
65.7             68 (14)             278
76.2             65 (14)            10.212
NSTE-ACS
82.6             56 (9)              132Abreu P, 1993 
71                65                 55Fernandes A, 1993
80                64 (11)            387Timóteo AT  ,2003
68.3             69                 802 Teixeira R, 2009
66.6             68 (12)            9.314Santos JF, 2009
Santos JF, 2009 68.3             65 (12)            2.956
81                63.7 (10.9)      389Calé R, 2010
80.1             66.4 (10.6)      614Raposo L, 2010
77.4             64.0 (10.5)      234Carmo P, 2011
MixedACS
67                62.2 (13.7)      191Fernando PB, 1996
82.5             56 (12)            178Caires G, 1998
72.9             65.1 (12.9)      1.366Morais J, 2001
0                  43                 33Adão L, 2004
77.2             57.0              104Sampaio F, 2006
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Figure  3  Proportion  of  acute  coronary  syndrome  patients  treated  with  PCI  in  Portugal,  estimated  in  unselected  samples  of
patients. F:  first  episode;  mixed  ACS:  mixture  of  patients  with  several  types  of  ACS; NSTE-ACS:  90%  or more  patients  with  diagnosis
of non-ST-segment  elevation  ACS;  PCI:  percutaneous  coronary  intervention;  R: recurrent  episode;  STEMI:  90%  or  more  patients  with
diagnosis of  ST-segment  elevation  myocardial  infarction  or  Q-wave  myocardial  infarction.  *  Age  is  presented  as mean  (SD)  unless
otherwise specified; † mean  age; ‡ median  age.
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acute  event,  was  performed  in approximately  half  of  STEMI
patients  according  to a  report  from  Faro  in  200820 and the
report  of  the  National  Registry  of  Acute  Coronary  Syndromes
covering  several  years  and centers  across  the  country.6 For
NTSE-ACS,  two  studies  published  in 1993  report  contrasting
experiences  in  small  single-center  samples,  while  from
2003  to  2011  several  estimates  consistently  point  to  one
third  to  one  half  of patients  being  revascularized  percu-
taneously  during  the  acute  hospitalization,  with  no  clear
time  trend.  With  a larger  number  of reports  and  more  reg-
ular  publication  over  15 years,  the  proportion  of  mixed
ACS  patients  revascularized  percutaneously  increased  from
under  10%  in  the  mid-1990s  to  approximately  70%  in recent
years  (Figure  3).
CABG  was  used in 1.0%  of  STEMI  patients  (this  figure
available  only  from  the  National  Registry  of  Acute  Coro-
nary  Syndromes).  In  NSTE-ACS  and  mixed  ACS,  1--10% of
patients  were  reported  as  undergoing  CABG,  with  no  clear
time  trend.  An exception  for  several  reports  is  a  single  insti-
tution  (Hospital  de  Santa  Cruz,  in  Carnaxide)  over  the  years,
with  a  proportion  closer  to  20% of  NTSE-ACS  patients  having
undergone  surgical  revascularization  during  hospitalization
for the  acute  event  (Figure 4).
Discussion
Despite  considerable  heterogeneity  in  the methodology  and
presentation  of  results  of  available  studies,  this  review
shows  that  the  proportion  of  ACS  patients  in Portugal  treated
with  fibrinolysis  has  decreased  in  the  last  20  years  and  the
use  of  PCI  has increased,  while  the use  of CABG  has not
changed.
Since  the  late  1970s,  more  aggressive  and  effective
treatments  have  been  developed  and implemented  for  the
treatment  of  CHD, including  fibrinolysis,  PCI  and  CABG.21 Of
the  primary  studies  included  in the present  review,  the old-
est  with  data  on  fibrinolysis  was  published  in 1989,22 while
PCI  and  CABG  were  first  mentioned  in an article  published
in 1993  (data  collection  in 1982).23 Data  from  previous  years
were  reported  in a few  publications  which were  excluded
mainly  due  to  the  reporting  format,  for  example  lack  of  data
on  sample  size  or  patients’  sex  and age,  or  because  the  use
of  procedures  in  the acute  hospitalization  or  over  variable
follow-up  periods  could  not be  distinguished.
During  the  last  decade,  mechanical  or  pharmacological
reperfusion  therapy  has  been  recommended  for  all  patients
with  STEMI  who  present  within  12 hours  of  the  onset  of
symptoms.24--26 A growing  body of evidence  has  also  demon-
strated  beneficial  effects  of  reperfusion  therapy  in patients
presenting  more  than  12  hours  from  symptom  onset.  In  this
group  of patients,  recent recommendations  consider  this
treatment  a strong  indication,  preferably  by  primary  PCI
(class  I) if there  is  evidence  of  ongoing  ischemia  or  if pain
and  electrocardiographic  changes  have been  stuttering.
Primary  PCI  may  be also  considered  even  in  asymptomatic
patients  presenting  12--24 hours  after  symptom  onset.25
For  years,  fibrinolysis  was  chosen  over  primary  PCI,  mainly
due  to  its  greater  ease  of  access  and  use.21 However,
mechanical  reperfusion  has  been  preferred  since  several
randomized  clinical  trials  and  meta-analyses  comparing
primary  PCI  with  in-hospital  fibrinolytic  therapy  in  patients
presenting  within  6--12  hours  of symptom  onset  showed
more  effective  restoration  of vessel  patency,  less  reoc-
clusion,  reinfarction  and  stroke,  improved  left  ventricular
function  and  less  short-term  mortality  with  primary  PCI.27,28
National6,29 and international  registries  in  Europe30,31
and  the USA32,33 suggest  an  increase  in the use  of  reper-
fusion  therapies  accompanied  by  a significant  shift  from
fibrinolysis  therapy  to  primary  PCI. A  significant  decrease
in  mortality  after  STEMI  has  been  observed  in countries
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switching  from fibrinolysis  to  primary  PCI.34 In our study,
we  observed  decreased  use  of  fibrinolysis  and  increased
use  of  primary  PCI.  In this  review,  most of the  studies
providing  data  on  fibrinolysis  were  published  in the 1990s,
with  data  collected  in the  1980s  and  1990s.  By  contrast,  the
studies  addressing  primary  PCI  were  only published  in the
current  century.  Although  the  trends  cannot  be  quantified,
fibrinolysis  appears  to  have  been  replaced  by  primary  PCI.
Since  its  introduction  in 1977, angioplasty  has  become
the  most  frequently  performed  major  intervention  in
medicine,35 as both  a reperfusion  (primary  PCI)  and revascu-
larization  procedure.  Among  the  included  studies  addressing
the  use  of  revascularization  by  a  percutaneous  procedure,
one  sixth  were published  in the 1990s  and  the  remainder
afterwards.  Surgical  revascularization  with  CABG  was  first
introduced  in 1969,  and  become  the  most  thoroughly  stud-
ied  procedure  in  the history  of  surgery.36 In our  review,
a  quarter  of the studies  were  published  in  the 1990s  and
the  remainder  after  2000.  Although  the primary  studies
provided  information  on  surgeries  performed  at different
times  related  to  the  acute  event  (e.g.  during  a variable
time  of  follow-up  after  the acute  event),  we  only  included
studies  with  data  on  CABG  performed  during  the  initial  hos-
pitalization.  Otherwise,  the data  to  be  compared  would be
even  more  heterogeneous.  Particularly  for this procedure,
it  is important  to  point  out  that  many  patients  referred
for  CABG  are  expected  to  have  undergone  surgery  after
discharge  or  have  been  transferred  to  a different  insti-
tution  while  awaiting  the procedure,6 thus  reducing  the
proportion  of  patients  treated  that  were  captured  by  this
analysis.
The  results  on  revascularization  therapies  are  consistent
with  the  findings  of  previous  studies  showing  an  increase  in
PCI  use  and  non-significant  changes  in use  of CABG  in recent
years.30,37,38 In patients  stabilized  after  an  episode  of acute
coronary  syndrome,  the choice  of revascularization  modal-
ity  can  be  made  as  in stable  coronary  heart  disease.25,39,40 In
single-vessel  disease,  which  occurs  in one-third  of  patients
with  ACS,  ad-hoc  PCI  is  feasible  in  most  cases,  whereas
in  patients  with  multivessel  disease  (approximately  half  of
cases)  the  decision  on  the  type  of revascularization  is  more
complex.41,42 Options  for  this condition  have  evolved  over
time,  and  currently  include  culprit  lesion  PCI,  multivessel
PCI,  CABG  or  hybrid (combined)  revascularization,  accord-
ing  to  clinical  status,  lesion  characteristics  and  the severity
and  distribution  of  coronary  artery  disease.25,39,40
Our  methodology  has  some  limitations.  The  use  of a
single  search  engine  may  have  limited  our  results.  However,
the  inclusion  of relevant  studies  identified  in  the reference
lists  of  the  review  articles  should  have helped  identify  older
and  non-PubMed-indexed  publications.  The  probability  of
identifying  relevant  studies  from  among  those  published
is  also  influenced  by  their  results  because,  despite  the
descriptive  nature  of  the  studies,  publication  bias  can
be  expected,  with  higher  likelihood  of  publication  from
higher-quality  or  at  least  higher-volume  centers.  It is
noteworthy  that  the  majority  of  studies  came  from  cardi-
ology  departments,  some of  which also  contributed  to  the
National  Registry  of  Acute  Coronary  Syndromes.  Therefore,
the  main  gain  with  this  review  is  its  coverage  of  a greater
time  span,  but  not  the  representation  of  less  specialized
centers  than  those  included  in  the National  Registry  of
Acute  Coronary  Syndromes.  The  results  are affected  by  the
methodological  heterogeneity  of  the  studies,  particularly
inclusion  criteria,  sample  size,  and patients’  age  and  sex,
as  well  as  the  relatively  small number  of  estimates  for
each  type of treatment  under  study.  Another  limitation  for
more  informative  conclusions  stems  from  the  small number
of  studies  with  sex-,  age-,  and  year-specific  estimates,  as
authors  mainly reported  overall  data.  Some  reported  data
referring  to  a  period  longer  than  one year;  however,  it was
not  possible  to  obtain  year-specific  estimates.
Given  these  limitations,  an  alternative  approach
to  the study  of  trends  in the use  of  these treatments  in  the
past  could  be  to  rely on  administrative  databases,  using
data  collected,  coded  and  stored,  immediately  available
for  analysis.43 The  national  register  of hospital  discharges29
could  be  used  to  quantify  the  number  of procedures
performed,  but  the usefulness  of these  datasets  is limited:
it  is  not  possible  to  classify  the subtypes  of ACS  according
to  current  recommendations44 when  departing  from data
coded  using  the  International  Classification  of  Diseases,
9th  revision,  Clinical  Modification  (ICD-9-CM).  Furthermore,
there  is  no  information  available  in  the  database  to  ascer-
tain  the  timing  of  PCI  or  to  identify  recurrent  episodes  in
the  same  patient.29
Conclusions
The  general  pattern  of  treatment  reflects  what  is  reported  in
other  developed  countries  and can  be viewed  as  a favorable
time  trend  in the quality  of care  of  ACS  patients.  Future
investigation  should focus  on  the  prospective  and  system-
atic  recording  of  high-quality  information  to  monitor  the
use  of  treatments  in  this  acute  condition,  while  past  trends
can  only be properly  clarified  by  an original  retrospective
study  on  a representative  sample  of  ACS  patients,  involving
review  of  hospital  records.
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